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SINGLE DOSE REGORAFENIB-INDUCED HYPERTENSIVE CRISIS
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Gastrointestinal stromal tumors (GISTs) are uncommon tumors of the gastrointestinal (GI) tract. Regorafenib is a new multikinase 
inhibitor and is approved for the treatment of GISTs in patients who develop resistance to imatinib and sunitinib. The most common 
drug-related adverse events with regorafenib are hypertension, hand-foot skin reactions, and diarrhea. Grade IV hypertensive side 
effect has never been reported after a single dose. In this report, we present a case of Grade IV hypertensive side effect (hyperten-
sive crisis and seizure) after a single dose of regorafenib. A 54-year-old male normotensive GIST patient was admitted to the emer-
gency department with seizure and encephalopathy after the first dosage of regorafenib. His blood pressure was 240/140 mmHg 
upon admission. After intensive treatment with nitrate and nitroprusside, his blood pressure returned to normal levels in five days. 
Regorafenib was discontinued, and he did not experience hypertension again. This paper reports the first case of Grade IV hyper-
tension after the first dosage of regorafenib. We can suggest that hypertension is an idiosyncratic side effect unrelated to the dosage.
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Gastrointestinal stromal tumors (GISTs) are un-
common tumors of the gastrointestinal (GI) tract. 
These tumors originate in very early forms of cells 
found in the wall of the GI tract called interstitial cells 
of Cajal [1]. GISTs usually have mutations in proto-on-
cogenic genes encoding the receptor tyrosine kinase 
(RTK) stem cell factor receptor (KIT) or platelet-de-
rived growth factor receptor alpha (PDGFR-α) [2–4]. 
The development of tyrosine kinase inhibitors that 
target the changes in these genes has improved 
the prognosis of GISTs. Imatinib and sunitinib inhibit 
multiple RTKs, including KIT and PDGFR-α, and are 
indicated for first- and second-line targeted therapy, 
respectively, in patients with GISTs [2].
Almost all patients develop resistance to these 
multikinase inhibitors [2]. Regorafenib is a new mul-
tikinase inhibitor and is approved for the treatment 
of GISTs in patients who develop resistance to imatinib 
and sunitinib and for metastatic colorectal cancer. 
This is a novel broad-spectrum kinase inhibitor, with 
activity against multiple targets, including vascular 
endothelial growth factor receptor (VEGF) 1, 2, 3, 
fibroblast growth factor receptor (FGFR) 1, PDGFR β, 
tyrosine kinase with immunoglobulin and epidermal 
growth factor homology domain 2 (TIE2) and the mu-
tant oncogenic kinases KIT, RET, B-RAF [5]. The most 
common drug-related adverse events with regorafenib 
are hypertension, hand-foot skin reactions, and diar-
rhea [6]. Grade IV hypertensive side effect has never 
been reported after a single dose.
In this report, we present a case of Grade IV hyper-
tensive side effect (hypertensive crisis and seizure) 
after a single dose of regorafenib.
Case report. A 54-year-old male was diagnosed with 
a 17×8 cm gastric mass by a CT scan. The patient under-
went partial gastric resection and removal of the mass. 
Immunohistochemical analysis revealed that the tumor 
was positive for CD117 and CD34 but negative for S100, 
and the patient was diagnosed with GIST. The CT scan 
showed hepatic and splenic metastasis 10 months after 
the surgery. The patient received imatinib treatment 
at 400 mg/day and was examined every three months. 
A CT scan at the 15th month of imatinib treatment showed 
progression in the size of the metastasis and new lymph 
nodes. We discontinued imatinib and prescribed sunitinib 
50 mg/day (28 days on, 14 days off). A CT scan at the 28th 
month of sunitinib treatment showed tumor progression. 
Therefore, sunitinib treatment was changed to oral rego-
rafenib 160 mg/day.
The patient was normotensive and had no previous 
history of high blood pressure. He was not receiving 
any medication except imatinib and sunitinib. The pa-
tient had routinely taken his blood pressure since com-
mencing the tyrosine kinase inhibitor treatment. Eight 
hours after the first dosage of regorafenib, the patient 
was admitted to the emergency department with 
seizure and encephalopathy. His blood pressure was 
240/140 mmHg upon admission. A cranial CT scan 
was performed and excluded metastasis. All blood 
workup was normal, including liver, kidney, and thyroid 
function. Echocardiography was normal.
After intensive treatment with nitrate and nitroprus-
side, his blood pressure returned to normal levels 
in five days. Regorafenib was discontinued, and he did 
not experience hypertension again. After all work-up, 
the case suggests that hypertensive crisis was related 
to the single dose of regorafenib treatment.
Regorafenib is a novel oral multikinase inhibitor that 
regulates tumor angiogenesis. In common with other 
antiangiogenic drugs targeting the VEGF/VEGFR path-
way, one of the dose-limiting side effects of regorafenib 
is hypertension [6]. A number of mechanisms have 
been suggested for VEGF signaling pathway inhibi-
tor associated hypertension. According to one study, 
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VEGFR pathway inhibitors decrease NO synthesis and 
lead to a loss of parallel capillary circulation in normal, 
nontumor tissue, a process called rarefaction. Other 
studies suggested a role for endothelial dysfunction, 
leading to an increase in endothelin-1 (ET-1) and aortic 
stiffness [7–10]. De Jesus-Gonzalez et al. [11] showed 
that regorafenib induces coordinated and reversible 
suppression of NO and stimulation of ET-1.
Two phase III studies of regorafenib have been 
performed. In the CORRECT study, which included 
patients with metastatic colorectal cancer, 36.7% 
of 500 patients in the regorafenib group had hyperten-
sion [12]. Treatment-related Grade III hypertension oc-
curred in only 7% of cases. Grade IV hypertension was 
not reported in this study. In the second rando mized, 
placebo-controlled, phase III trial of patients with ad-
vanced GISTs, regorafenib-induced hypertension was 
seen in 49% of 132 patients [6]. Among these, 23% 
had Grade III hypertension, and only one patient had 
Grade IV hypertension. The study contained no data 
on the patient’s dosage or the duration of regorafenib 
treatment.
George et al. [13] and Bruix et al. [14] reported 
regorafenib-induced hypertension in 36% of patients 
in two phase II studies (n = 33 and n = 36, respec-
tively). All the patients in George et al. [13] study had 
Grade III hypertension. Bruix [14] reported a patient 
with Grade ≥III hypertension, but the actual grade 
was not reported whether grade III or IV in the study. 
Eisen et al. [15] showed that only 3 of 49 patients had 
Grade ≤IV hypertension during regorafenib usage 
in their phase II clinical trial.
In conclusion, this paper reports the first case 
of Grade IV hypertension after a single dose of rego-
rafenib. Grade IV hypertension is an unexpected adverse 
effect of regorafenib therapy according to the afore-
mentioned five clinical trials. These studies included 
750 patients, and only one case of Grade IV hyperten-
sion was reported. Our patient experienced Grade IV hy-
pertension after a single dose of regorafenib treatment, 
and the hypertension ceased after discontinuation 
of the drug. Our findings suggest that hypertension 
is an idiosyncratic side effect unrelated to the dosage.
REFERENCES
1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-
function mutations of c-kit in human gastrointestinal stromal 
tumors. Science 1998; 79: 77–80.
2. Lamba G, Gupta R, Lee B, et al. Current management and 
prognostic features for gastrointestinal stromal tumor (GIST). 
Exp Hematol Oncol 2012; 1: 14. doi:10.1186/2162–3619–1-14.
3. Ganjoo KN, Patel S. Current and emerging pharmaco-
logical treatments for gastrointestinal stromal tumour. Drugs 
2011; 71: 321–30.
4. Aprile G, Macerelli M, Giuliani F. Regorafenib for gastro-
intestinal malignancies: from preclinical data to clinical results 
of a novel multi-target inhibitor. Bio Drugs 2013; 27: 213–24.
5. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib 
(BAY 73–4506): a new oral multikinase inhibitor of angioge-
nic, stromal and oncogenic receptor tyrosine kinases with 
potent preclinical antitumor activity. Int J Cancer 2011; 
129: 245–55.
6. Demetri GD, Reichardt P, Kang YK, et al. Efficacy 
and safety of regorafenib for advanced gastrointestinal stromal 
tumours after failure of imatinib and sunitinib (GRID): an in-
ternational, multicentre, randomised, placebo-controlled, 
phase 3 trial. Lancet 2013; 381: 295–302.
7. Robinson ES, Khankin EV, Choueiri TK, et al. Sup-
pression of the nitric oxide pathway in metastatic renal cell 
carcinoma patients receiving vascular endothelial growth 
factor-signaling inhibitors. Hypertension 2010; 56: 1131–6.
8. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure 
rise following angiogenesis inhibition by bevacizumab: a crucial 
role for microcirculation. Ann Oncol 2008; 19: 927–34.
9. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension 
and rarefaction during treatment with telatinib, a small molecule 
angiogenesis inhibitor. Clin Cancer Res 2008; 14: 3470–6.
10. Nazer B, Humphreys BD, Moslehi J. Effects of novel 
angiogenesis inhibitors for the treatment of cancer on the car-
diovascular system: focus on hypertension. Circulation 2011; 
124: 1687–91.
11. de Jesus-Gonzalez N, Robinson E, Penchev R, et al. 
Regorafenib Induces Rapid and Reversible Changes in Plasma 
Nitric Oxide and Endothelin-1. Am J Hypertens 2012; 25: 1118–
23.
12. Grothey A, Van Cutsem E, Sobrero A, et al. Rego-
rafenib monotherapy for previously treated metastatic 
colorectal cancer (CORRECT): an international, multicentre, 
randomised, placebo-controlled, phase 3 trial. Lancet 2013; 
381: 303–12.
13. George S, Wang Q, Heinrich MC, et al. Efficacy and 
safety of regorafenib in patients with metastatic and/or unre-
sectable GI stromal tumor after failure of imatinib and suni-
tinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401–7.
14. Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib 
as second-line therapy for intermediate or advanced hepato-
cellular carcinoma: Multicentre, open-label, phase II safety 
study. Eur J Cancer 2013; 49: 3412–9.
15. Eisen T, Joensuu H, Nathan PD, et al. Regorafenib 
for patients with previously untreated metastatic or unresect-
 Copyright © Experimental Oncology, 2014 
